Schwan follows Franz, Schinecker follows Schwan.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 710 entries already.
Entries by Thomas Gabrielczyk
This new investment will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients (APIs), particularly the highly potent drugs (HPAPIs) used to treat cancer.
Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, announced it has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million (>$1 billion) since inception in […]
BioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including new investors such as AXA Investment Managers and a US institutional investor and the existing shareholders Forbion, HBM Healthcare Investments, Redmile Group, Invus, the Fourth National Swedish Pension […]
Immunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline.
A current Nature study specifies the most competitive health biotech sectors worldwide and puts Switzerland at the top, Sweden second and the USA third. Does the new math convince?
GlaxoSmithKline (GSK), one of the UKs large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK to demerge on 6, July, first trading day is today, 18th of July.
European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS).
Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (38.4 million), bringing the total Series B amount raised to $114 million. Pfizer led the extension with an investment through its Pfizer Breakthrough Growth Initiative.
Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration, a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures […]